Seagen, a wholly owned subsidiary of Pfizer

51 total trials 35 currently recruiting 2 completed

Trial Pipeline

RECRUITING Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892

RECRUITING Phase 1

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT06131840

RECRUITING Phase 1

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT05208762

RECRUITING Phase 3

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651

RECRUITING Phase 2

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329

RECRUITING Phase 1

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

NCT04227847

RECRUITING Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632

ACTIVE NOT RECRUITING Phase 1

A Study of SGN-MesoC2 in Advanced Solid Tumors

NCT06466187

ACTIVE NOT RECRUITING Phase 1

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

NCT06254495

ACTIVE NOT RECRUITING Phase 3

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435

ACTIVE NOT RECRUITING Phase 2

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NCT06003231

ACTIVE NOT RECRUITING Phase 1

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

NCT05983133

ACTIVE NOT RECRUITING Phase 3

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295

ACTIVE NOT RECRUITING Phase 1

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

NCT05571839

ACTIVE NOT RECRUITING Phase 3

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582

ACTIVE NOT RECRUITING Phase 2

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380

ACTIVE NOT RECRUITING Phase 2

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT04430738

ACTIVE NOT RECRUITING Phase 3

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283

ACTIVE NOT RECRUITING Phase 3

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

NCT03975647

ACTIVE NOT RECRUITING Phase 1

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

NCT03786081

ACTIVE NOT RECRUITING Phase 2

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

NCT03485209

COMPLETED Phase 3

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

NCT04697628

COMPLETED Phase 2

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032

What the Pipeline for Seagen, a wholly owned subsidiary of Pfizer Shows

According to the ClinicalTrials.gov registry, Seagen, a wholly owned subsidiary of Pfizer is linked to 51 US clinical trials across every stage of research activity. Of those, 35 studies are currently recruiting — about 69% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 4% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Seagen, a wholly owned subsidiary of Pfizer reports 7 late-stage studies (Phase 3 and Phase 4 combined) and 44 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Seagen, a wholly owned subsidiary of Pfizer is Carcinoma, Non-Small-Cell Lung with 8 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial